Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Yao WangChengxia JiangXiaolin DongMingwei ChenQin GuLihui ZhangYanqin FuTianrong PanYan BiWeihong SongJing XuWeiPing LuXiaodong SunZi YeDanli ZhangLiang PengXiang LinWei DaiQuanren WangWenying YangPublished in: Diabetes, obesity & metabolism (2024)
For patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy, the co-administration of retagliptin and henagliflozin yielded more effective glycaemic control through 24 weeks compared with the individual agents at their corresponding doses.
Keyphrases
- double blind
- placebo controlled
- end stage renal disease
- clinical trial
- open label
- ejection fraction
- phase iii
- type diabetes
- chronic kidney disease
- newly diagnosed
- study protocol
- phase ii
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- gestational age
- smoking cessation